| Drug name: Ibrutinib (formerly PCI-32765) |
| Phase: IV (approved worldwide) |
| Indication: Chronic lymphocytic leukemia (all patients in the United States, relapsed/refractory or with deletion 17p in other countries) |
| Pharmacology description/mechanism of action: Irreversible (covalent) inhibitor of Bruton’s tyrosine kinase, an important mediator of B-cell receptor signaling |
| Route of administration: Oral; 3 capsules (140 mg each) per day |
Chemical structure:
|
| Pivotal trials: RESONATE [9] RESONATE-17 [11] RESONATE-2 [6] |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.